PE20061122A1 - Composiciones que incluyen hierro - Google Patents

Composiciones que incluyen hierro

Info

Publication number
PE20061122A1
PE20061122A1 PE2005001394A PE2005001394A PE20061122A1 PE 20061122 A1 PE20061122 A1 PE 20061122A1 PE 2005001394 A PE2005001394 A PE 2005001394A PE 2005001394 A PE2005001394 A PE 2005001394A PE 20061122 A1 PE20061122 A1 PE 20061122A1
Authority
PE
Peru
Prior art keywords
iron
forms
chelated
absorption
chelates
Prior art date
Application number
PE2005001394A
Other languages
English (en)
Inventor
Jonathan David Bortz
Mitchell I Kirschner
David S Hermelin
Original Assignee
Drugtech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drugtech Corp filed Critical Drugtech Corp
Publication of PE20061122A1 publication Critical patent/PE20061122A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE DE 10 mg A 500 mg DE UNA O MAS FORMAS DE HIERRO Y DE 5 mg A 500 mg DE UNA O MAS FORMAS DE UN ACIDO ORGANICO. LA COMPOSICION COMPRENDE ADEMAS 5 mg A 500 mg DE UNO O MAS ESTIMULANTES DE LA ABSORCION DE HIERRO Y DE 5 mg A 500 mg DE ACIDO ASCORBICO. EL HIERRO SE SELECCIONA DE UN GRUPO QUE CONSISTE EN HIERRO CARBONILO, HIERRO QUELADO, SALES DE HIERRO SOLUBLE, COMPLEJO DE HIERRO QUELADO TAL COMO QUELATOS BIS-GLICINOS DE HIERRO, QUELATOS AMINOACIDOS DE HIERRO. LA COMPOSICION PROPORCIONA SUPLEMENTOS DIETETICOS QUE ESTIMULAN O MANTIENEN LA ABSORCION DE HIERRO MEDIANTE LA ADMINISTRACION DE HIERRO CON UN ACIDO ORGANICO Y ES UTIL EN EL TRATAMIENTO DE ANEMIAS O DESORDENES RELACIONADOS CON LA DEFICIENCIA DE HIERRO
PE2005001394A 2004-12-22 2005-12-01 Composiciones que incluyen hierro PE20061122A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11/020,801 US20060134227A1 (en) 2004-12-22 2004-12-22 Compositions including iron

Publications (1)

Publication Number Publication Date
PE20061122A1 true PE20061122A1 (es) 2006-10-16

Family

ID=36596132

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001394A PE20061122A1 (es) 2004-12-22 2005-12-01 Composiciones que incluyen hierro

Country Status (11)

Country Link
US (5) US20060134227A1 (es)
EP (2) EP1827418A4 (es)
JP (2) JP2008525442A (es)
CN (1) CN101102762A (es)
AR (1) AR052837A1 (es)
AU (1) AU2005319679A1 (es)
BR (1) BRPI0519265A2 (es)
CA (1) CA2591996A1 (es)
MX (1) MX2007008021A (es)
PE (1) PE20061122A1 (es)
WO (2) WO2006068697A2 (es)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US20070065542A1 (en) * 2005-09-20 2007-03-22 Board Of Regents, The University Of Texas System Enhanced solubility of preformed calcium citrate by adding citric acid
CA2625375A1 (en) * 2005-10-11 2007-04-19 Bayer Consumer Care Ag Mixture of iron and copper salts masking mettalic taste
EP1790356A1 (de) * 2005-11-24 2007-05-30 Vifor (International) Ag Präparat, umfassend Eisen(III)-Komplexverbindungen und redoxaktive Substanz(en)
PT1973549T (pt) 2006-01-06 2016-10-25 Luitpold Pharm Inc Métodos e composições para administração de ferro
CA2664406A1 (en) * 2006-09-28 2008-04-03 Bayer Consumer Care Ag Mixture of iron and copper salts masking metallic taste
US8178132B2 (en) 2007-03-22 2012-05-15 Magceutics, Inc. Magnesium-containing food compositions
JP2010522216A (ja) * 2007-03-22 2010-07-01 リュー，グオソン マグネシウム組成物およびその使用
US7816404B2 (en) * 2007-07-20 2010-10-19 Rockwell Medical Technologies, Inc. Methods for the preparation and use of ferric pyrophosphate citrate chelate compositions
US20090047362A1 (en) * 2007-08-13 2009-02-19 Keith Edward Forrester Method for in-vitro stabilization of heavy metals
US9125844B1 (en) 2007-09-25 2015-09-08 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
US7964189B1 (en) 2007-09-25 2011-06-21 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
ITMI20071979A1 (it) * 2007-10-12 2009-04-13 Massimo Baldacci Formulazioni farmaceutiche contenenti ferro bisglicinato chelato
US20090124572A1 (en) * 2007-11-09 2009-05-14 Deanna Jean Nelson Iron-containing nutritional supplement
US8535660B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
US8535659B1 (en) 2008-05-27 2013-09-17 Argent Development Group, Llc Nutritional supplements for pregnant women
US8996104B2 (en) 2008-06-25 2015-03-31 Fe3 Medical, Inc. Patches and method for the transdermal delivery of a therapeutically effective amount of iron
WO2010036977A2 (en) * 2008-09-25 2010-04-01 New England Medical Center Hospitals, Inc. Combination therapies with topiramate for seizures, restless legs syndrome, and other neurological conditions
CN102292428B (zh) * 2009-01-30 2014-06-04 埃科莱布有限公司 羟基羧酸铝助洗剂的开发
US8202830B2 (en) 2009-01-30 2012-06-19 Ecolab Usa Inc. Development of an aluminum hydroxydicarboxylate builder
US8821945B2 (en) 2009-04-25 2014-09-02 Fe3 Medical, Inc. Method for transdermal iontophoretic delivery of chelated agents
WO2010136839A1 (en) * 2009-05-29 2010-12-02 Carlo Ghisalberti Use of deferoxamine and related compounds in targeted delivery forms to treat an inflammatory bowel disease
US8178709B2 (en) * 2009-07-21 2012-05-15 Biolink Life Sciences, Inc. Iron preparation suitable for pharmaceutical formulation and process for the preparation thereof
RU2563819C2 (ru) 2009-07-21 2015-09-20 Керикс Байофармасьютикалз, Инк. Лекарственные формы цитрата железа (iii)
US8536106B2 (en) 2010-04-14 2013-09-17 Ecolab Usa Inc. Ferric hydroxycarboxylate as a builder
JP5357102B2 (ja) * 2010-04-27 2013-12-04 日本炉機工業株式会社 石化遺骨灰の製造方法
EP2420243A1 (en) 2010-08-18 2012-02-22 Inovativo Biomedicinas Tehnologiju Instituts, SIA Compositions obtainable from bred beetroot juice to promote iron absorption and blood forming
IT1402142B1 (it) * 2010-09-24 2013-08-28 Just Pharma S R L Formulazione integrativa finalizzata al controllo delle alterazioni multifattoriali ricorrenti nell'anemia da carenza di ferro e per colmare eventuali carenze o aumentati fabbisogni nutrizionali in alcune condizioni fisiopatologiche.
EP2497380A1 (en) * 2011-03-10 2012-09-12 DSM IP Assets B.V. Process for iron supplementation of beverages
AR086606A1 (es) 2011-05-31 2014-01-08 Vifor Int Ag Compuestos del complejo de fe(iii) para el tratamiento y profilaxis de los sintomas de la deficiencia de hierro y las anemias por deficiencia de hierro
CA2849732C (en) * 2011-09-22 2019-10-01 Jonathan Bortz Buffered upper gi absorption promoter
JP2015535209A (ja) * 2012-06-21 2015-12-10 ケリク バイオファーマシューティカルス， インコーポレーテッド 慢性腎臓病患者の治療におけるクエン酸第二鉄の使用
EP2895179A4 (en) * 2012-09-11 2016-04-06 Dakota Star Capital Llc IRON COMPRISING A NUTRITIONAL SUPPLEMENT
CN102961338B (zh) * 2012-12-07 2015-03-18 青岛黄海制药有限责任公司 一种多糖铁缓释微丸制剂及其制备方法
ES2895044T3 (es) 2013-06-06 2022-02-17 Albion Laboratories Inc Suplemento de hierro
CN105491897B (zh) * 2013-08-28 2018-07-06 帝斯曼知识产权资产管理有限公司 肉汤浓缩物的铁补充
EP3038475B1 (en) * 2013-08-28 2018-06-27 DSM IP Assets B.V. Iron supplementation of a bouillon concentrate
EP3042652B1 (en) * 2013-09-05 2018-08-29 Profeat Biotechnology Co. Ltd. Use of composition containing ferrous amino acid chelate in preparation of anti-cancer medicament
TWI483721B (zh) 2013-09-05 2015-05-11 Profeat Biotechnology Co Ltd The use of a composition containing a ferrous amino acid chelate for the manufacture of anti-cancer medicaments
US9492421B1 (en) 2013-11-14 2016-11-15 Argent Development Group, Llc Nutritional supplements for treatment of iron deficiency anemia
US9629846B1 (en) 2013-11-14 2017-04-25 Argent Development Group, Llc Nutritional supplements for women desiring to become pregnant, and pregnant and nursing women
CN104644557B (zh) * 2013-11-22 2017-10-31 上海宣泰医药科技有限公司 卟啉铁固体分散体及其制备方法
JP2014051535A (ja) * 2013-12-19 2014-03-20 Fujifilm Corp 鉄、カルシウム、又はマグネシウムの吸収を促進する方法
CN104887696B (zh) * 2014-03-04 2018-06-29 天津怀仁制药有限公司 右旋糖酐铁和维生素c的复方制剂
EP3179249A4 (en) * 2014-08-05 2017-07-26 Fujifilm Corporation Nucleated erythrocyte sorting method
ES2966909T3 (es) 2014-08-13 2024-04-25 Akeso Biomedical Inc Compuestos y composiciones antimicrobianos, y usos de los mismos
GB201416293D0 (en) * 2014-09-15 2014-10-29 Solvotrin Therapeutics Ltd Methods and preparations
JP5757493B1 (ja) * 2014-09-24 2015-07-29 富田製薬株式会社 経口型鉄分補給用固形組成物及びその製造方法
US10913705B2 (en) * 2014-11-07 2021-02-09 Npa—Núcleo De Pesquisas Aplicadas Ltda Iron amino acid compounds, method for preparing iron amino acid compounds, compositions containing iron amino acid compounds, and uses thereof
CN106999515B (zh) 2014-12-01 2020-10-02 普惠德生技股份有限公司 含有亚铁胺基酸螯合物的组合物在制备调控脂肪代谢的药物的用途
CN104474004A (zh) * 2014-12-09 2015-04-01 重庆综艺营养科技有限责任公司 改善贫血的赖氨酸螯合铁生血素
US20170360075A1 (en) * 2014-12-11 2017-12-21 The Penn State Research Foundation Medical food for the treatment of malaria and/or iron deficiency
DK3334440T3 (en) 2015-08-11 2021-07-26 Akeso Biomedical Inc Biofilm inhibiting compositions enhancing weight gain in livestock
US10653658B2 (en) 2015-08-11 2020-05-19 Akeso Biomedical, Inc. Biofilm inhibiting compositions enhancing weight gain in livestock
CN105476953B (zh) * 2015-09-01 2018-10-30 张伟 一种用于补铁的液体制剂及其制备方法
US11517555B2 (en) * 2015-09-04 2022-12-06 Rockwell Medical, Inc. Solid soluble ferric pyrophosphate formulations, kits, and methods using the same
JP6919117B2 (ja) * 2015-12-15 2021-08-18 三菱ケミカル株式会社 鉄化合物含有組成物の粒子、鉄化合物の変色抑制方法、並びに鉄化合物及びビタミンｃ含有組成物
EP3199167A1 (de) 2016-01-28 2017-08-02 G.L. Pharma GmbH Arzneimittel zur behandlung von eisenmangelzuständen mit folsäuredefizit
EP3429560A1 (en) * 2016-03-15 2019-01-23 Solvotrin Therapeutics Ltd. Compositions and methods for increasing iron intake in a mammal
KR102190963B1 (ko) * 2016-05-20 2020-12-15 옵쉐스트바 스 아그라니첸너이아트?洲뵈?벤너스찌유 ＂빅-즈다로비예쥐 보트니흐＂ 빈혈의 예방 및 치료를 위한 비타민을 함유하는 철 덱스트란 복합체의 즉시 사용가능한 주사 가능한 조성물
CA3023964A1 (en) * 2016-05-26 2017-11-30 Profeat Biotechnology Co., Ltd. Use of composition comprising ferrous amino acid chelate for manufacture of medicine for reducing lactic acid
CN106265731B (zh) * 2016-09-30 2019-07-19 广西科技大学 硫酸亚铁骨架型缓释滴丸的制备方法
CN110198709A (zh) * 2017-02-17 2019-09-03 普惠德生技股份有限公司 含有亚铁氨基酸螯合物的组合物用于制造治疗肝功能异常的医药品的用途
EP3681539A1 (en) * 2017-09-11 2020-07-22 Pharmacosmos Holding A/S Iron complex compounds for therapeutic use
CN108635370A (zh) * 2018-07-13 2018-10-12 山东达因海洋生物制药股份有限公司 一种含有右旋糖酐铁的组合物制剂及其制备方法
CN110464011A (zh) * 2018-08-07 2019-11-19 美安康质量检测技术（上海）有限公司 一种补血营养粉及其制备方法
EP3860621A4 (en) * 2018-10-05 2022-07-06 Ampersand Biopharmaceuticals, Inc. IRON FORMULATIONS FOR TOPICAL ADMINISTRATION AND METHODS OF TREATMENT OF IRON DEFICIENCY
MX2021005095A (es) * 2018-10-31 2021-06-15 My Or Diagnostics Ltd Personalized food products for ensuring adequate iron intake.
TWI710370B (zh) * 2018-12-20 2020-11-21 普惠德生技股份有限公司 含有亞鐵胺基酸螯合物粒子的組合物用於製備治療或減緩阿茲海默症或帕金森氏症的醫藥品的用途
JP6998087B2 (ja) * 2018-12-20 2022-02-04 普惠徳生技股▲ふん▼有限公司 第一鉄アミノ酸粒子を含む組成物、およびその組成物を含む、膵臓関連疾患の治療または改善のための薬剤
CN112168843A (zh) * 2019-07-05 2021-01-05 普惠德生技股份有限公司 经烧结的纳米粒子及其抗病毒的用途
US20230012448A1 (en) * 2021-06-30 2023-01-12 Getwing Biotechnology Medical Co., Ltd Methods for alleviating kidney disease and fibrosis of organ
WO2023272693A1 (zh) * 2021-07-01 2023-01-05 思瑰瑞保健食品有限公司 一种维生素c加硫酸亚铁缓控释片及其制备方法
WO2023023029A1 (en) * 2021-08-16 2023-02-23 Thermolife International, Llc Iron supplement compositions and methods of use thereof
CN114028423B (zh) * 2021-12-13 2023-05-23 广东粤港澳大湾区国家纳米科技创新研究院 修饰的纳米氧化铁在制备预防和/或治疗炎性肠病的药物中的应用
CN114288320A (zh) * 2021-12-29 2022-04-08 珠海天翼医药技术开发有限公司 一种猪用口服补铁剂及其制备方法
CN114767710B (zh) * 2022-04-12 2023-07-07 中山大学 甘氨酸亚铁在治疗类风湿关节炎中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB933108A (en) * 1960-02-03 1963-08-08 Haessle Ab Improvements in or relating to pharmaceutical iron preparations
GB1266356A (es) * 1968-08-08 1972-03-08
GB1292820A (en) * 1969-08-28 1972-10-11 Aspro Nicholas Ltd Haematinic preparations
GB1338071A (en) * 1970-11-25 1973-11-21 Laso Martinez V Pharmaceutical iron preparations
US3773929A (en) * 1972-11-02 1973-11-20 Diagnostic Data Inc Pharmaceutical compositions comprising orgotein and their use
US4362710A (en) * 1980-07-04 1982-12-07 Nissan Gosei Kogyo Co., Ltd. Feeds for baby pigs, process for preparing the same and method of breeding baby pigs
US4599152A (en) * 1985-05-24 1986-07-08 Albion Laboratories Pure amino acid chelates
US4863898A (en) * 1986-02-06 1989-09-05 Albion International, Inc. Amino acid chelated compositions for delivery to specific biological tissue sites
US4752479A (en) * 1986-05-27 1988-06-21 Ciba-Geigy Corporaton Multi vitamin and mineral dietary supplement with controlled release bioavailable iron
US4830716B1 (en) * 1986-07-03 1999-12-07 Albion Int Preparation of pharmaceutical grade amino acid chelates
US4822816A (en) * 1987-04-10 1989-04-18 Oxycal Laboratories, Inc. Compositions and methods for administering vitamin C
US5070085A (en) * 1987-04-10 1991-12-03 Oxycal Laboratories, Inc. Compositions and methods for administering therapeutically active compounds
FR2642420B1 (fr) * 1989-01-27 1991-09-06 Valpan Sa Labo Pharma Nouvelle forme galenique a liberation programmee contenant une association de sels ferreux, d'acide succinique et d'acide ascorbique
JPH0674206B2 (ja) * 1989-12-28 1994-09-21 田辺製薬株式会社 放出制御型製剤およびその製法
US6451341B1 (en) * 1990-02-05 2002-09-17 Thomas J. Slaga Time release formulation of vitamins, minerals and other beneficial supplements
HU207799B (en) * 1991-07-24 1993-06-28 Beres Export Import Rt Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis
US5662922A (en) * 1992-01-20 1997-09-02 Christensen; Borge Holm Iron-containing composition for the prevention of anaemia and a method for producing the composition
US5516925A (en) * 1994-08-23 1996-05-14 Albion International, Inc. Amino acid chelates having improved palatability
JP2590449B2 (ja) * 1995-04-21 1997-03-12 農林水産省畜産試験場長 新生子牛の造血機能の改善及び貧血の予防方法
DE69623326T2 (de) * 1995-10-27 2003-05-15 Procter & Gamble Farbestabile mit eisen, zink und vitaminen angereicherte trockene getränkgemischen
US5770226A (en) * 1996-07-10 1998-06-23 Wake Forest University Combined pharmaceutical estrogen-androgen-progestin oral contraceptive
CA2230801A1 (en) * 1998-02-27 1999-08-27 Stanley H. Zlotkin Composition comprising micro-encapsulated iron
US6495177B1 (en) * 1999-08-13 2002-12-17 Warner Chilcott Laboratories Ireland Limited Orally dissolvable nutritional supplement
US6521247B1 (en) * 1999-08-13 2003-02-18 Warner Chilcott Laboratories Ireland Limited Dual iron containing nutritional supplement
JP2003520846A (ja) * 2000-01-28 2003-07-08 ザ プロクター アンド ギャンブル カンパニー 心血管系の健康用の風味の良いアルギニン化合物およびその使用
US20020013331A1 (en) * 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
US6924273B2 (en) * 2000-10-03 2005-08-02 Scott W. Pierce Chondroprotective/restorative compositions and methods of use thereof
US6716814B2 (en) * 2001-08-16 2004-04-06 Albion International, Inc. Enhancing solubility of iron amino acid chelates and iron proteinates
US6906038B2 (en) * 2001-08-29 2005-06-14 Abbott Laboratories Methods for alleviating mucositis
US20030190355A1 (en) * 2002-04-05 2003-10-09 Hermelin Marc S. Modified release minerals
US7994217B2 (en) * 2002-05-02 2011-08-09 Xanodyne Pharmaceuticals, Inc. Prenatal multivitamin/multimineral supplement
US20060148690A1 (en) * 2002-07-08 2006-07-06 Lydie Bougueleret Secreted peptides
US20030045473A1 (en) * 2002-07-19 2003-03-06 Sarama Robert Joseph Compositions, kits, and methods for cardiovascular health
US8007846B2 (en) * 2006-01-18 2011-08-30 Albion International, Inc. Mixed amino acid/mineral compounds having improved solubility

Also Published As

Publication number Publication date
US20090028962A1 (en) 2009-01-29
WO2006068697A2 (en) 2006-06-29
US20160022631A1 (en) 2016-01-28
EP1827419A2 (en) 2007-09-05
CN101102762A (zh) 2008-01-09
WO2006068729A2 (en) 2006-06-29
US20060134227A1 (en) 2006-06-22
AR052837A1 (es) 2007-04-04
MX2007008021A (es) 2008-04-11
US20110015150A1 (en) 2011-01-20
JP2008525445A (ja) 2008-07-17
JP2008525442A (ja) 2008-07-17
EP1827418A2 (en) 2007-09-05
EP1827418A4 (en) 2011-08-24
CA2591996A1 (en) 2006-06-29
AU2005319679A1 (en) 2006-06-29
WO2006068729A3 (en) 2007-01-18
EP1827419A4 (en) 2011-08-17
BRPI0519265A2 (pt) 2009-01-06
US20130189374A1 (en) 2013-07-25
WO2006068697A3 (en) 2006-12-21

Similar Documents

Publication Publication Date Title
PE20061122A1 (es) Composiciones que incluyen hierro
TW200727903A (en) Stable pharmaceutical compositions of 5, 10 methylenetetrahydrofolate
BRPI0500704A (pt) composições de tratamento pessoal reidratáveis
AR047928A1 (es) Derivados de tetrahidropiridoindol
MX2007002398A (es) Nuevas composiciones farmaceuticas para el tratamiento de cancer.
MY144992A (en) Substituted 1,2,3,4-tetrahydroisoquinoline derivatives.
CY1115825T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν λεβετιρακεταμη και διαδικασια παρασκευης τους
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
CY1112831T1 (el) Παραγωγα αζαβιρηενυlαμινοβενζοιc acid σαν παραγοντες καταστολης dhodh
TN2009000137A1 (en) Substituted 2,3-dihydroimidazo[1,2-c]quinazoline derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
RS20080533A (en) Triazolopyrazine derivatives useful as anticancer agents
DE602006014579D1 (de) Heteroalkylgebundene pyrimidinderivate
PH12012501687A1 (en) Acetylcysteine composition and uses therefor
ECSP055618A (es) Terapia de combinacion para enfermedades hiperproliferativas
MX2010007523A (es) Nuevos derivados de pirazolo[3,4-d]pirimidina como farmacos anticancer.
ECSP055575A (es) Uso de derivados de tio-oxindol en el tratamiento de enfermedades de la piel.
WO2006020358A3 (en) Novel biphenyl compounds and their use
ECSP088745A (es) Derivados sustituidos de cromanol y su uso
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
DE60329994D1 (de) Selbstbräuner enthaltend wasserlösliche Vitamin B3-Komponente und Bräunungswirkstoff mit Alpha-Hydroxycarbonyl-Gruppierung
CR9857A (es) Composiciones de suplemento de hierro con tolerancia mejorada
TNSN08321A1 (en) Dimers of artemisinin derivatives, preparation thereof and therapeutic use thereof
DE602006009259D1 (de) Pharmazeutische zusammensetzung mit einem organopoirkstoff
BRPI0509667A (pt) azaquinazolinas substituìdas com eficácia antiviral
BRPI0508127A (pt) uso de uma composição consistindo essencialmente de uma mistura de ésteres alifáticos, composição para uso como agente de deslize num polìmero de poliéster, polìmero de poliéster

Legal Events

Date Code Title Description
FC Refusal